Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interferon alpha-5 (IFNA5)
- Target
- IFNA5
- Molecular classification
- Cytokine, Type I interferon (family), Secreted protein
01
Overview
Interferon alpha-5 is a secreted cytokine produced by immune cells such as macrophages in response to viral infection, mediating antiviral, antiproliferative, and immunomodulatory activities through binding to the type I interferon receptor. It stimulates the production of antiviral enzymes and initiates transcription of interferon-induced genes, contributing to defense against viruses and modulation of immune pathways[1][2][4][5][7]. Diseases associated with IFNA5 include cutaneous mastocytosis and hepatitis B, and its biological actions are leveraged therapeutically and experimentally through recombinant interferon alpha preparations[1][4].
- Other names
- Interferon alpha-5IFNA5IFN-alpha-5IFN-alphaGInterferon alpha-GInterferon alpha-61LeIF GINA5INFA5interferon alpha-5interferon alpha-Ginterferon alpha-61leIF G
02
Mechanism of action
Activation of JAK/STAT signaling via type I interferon receptor; Upregulation of antiviral genes and proteins; Modulation of immune cell activity
03
Biological functions
Antiviral activityImmune response modulationCell signaling (via type I interferon receptor)Lymphocyte activationInduction of enzymes involved in antiviral defense (protein kinase and oligoadenylate synthetase)
04
Disease associations
Infection (e.g., hepatitis B virus, viral defense)InflammationMastocytosis, cutaneousOther diseases modulated by immune/antiviral responses
05
Safety considerations
Flu-like symptoms (fever, fatigue)Myelosuppression (bone marrow suppression)Autoimmune phenomena (e.g., thyroiditis, lupus-like syndromes)Neuropsychiatric effects (depression, cognitive changes)
06
Interacting drugs
Recombinant interferon alpha products (clinically, various IFN-alpha preparations—exact subtype specificity of approved drugs is generally not limited to IFNA5, but IFNA5 shares activity profile)
1 more in the full profile.
07
Biomarkers
Expression of interferon-stimulated genesIFNA5 protein levels in serum/tissue (context-dependent; usually total IFN-alpha levels measured)Upregulation upon viral infection
Beyond the preview
Go deeper on Interferon alpha-5 (IFNA5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interferon alpha-5 (IFNA5).